Capital International Investors
ZBIO

Capital International Investors’s Zenas BioPharma ZBIO Stock Holding History

Capital International Investors’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$63.5M Buy
2,502,912
+68,912
+3% +$1.37M 0.01% 331
2026
Q1 		$47.6M Buy
+2,434,000
New +$54.6M 0.01% 335

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
RPSM
Royalty Pharma Sub-Manager New York $242M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital International Investors's ZBIO Position: Q2 2026 in Review

Capital International Investors increased its Zenas BioPharma (ZBIO) stake by 2.8% in Q2 2026, buying an estimated $1.37M and bringing the position to 2,502,912 shares worth $63.5M. The position accounts for 0.01% of the portfolio, ranked #331.

Capital International Investors first reported a position in ZBIO in Q1 2026 and has held it in 2 quarters since. 144 funds tracked by Wall St. Rank hold ZBIO as of Q2 2026.

  • Capital International Investors held 2,502,912 shares of Zenas BioPharma worth $63.5M as of Q2 2026.
  • Capital International Investors bought 68,912 Zenas BioPharma shares in Q2 2026, an estimated $1.37M.
  • Zenas BioPharma made up 0.01% of Capital International Investors's portfolio in Q2 2026, its #331 holding.
  • Capital International Investors first reported a position in Zenas BioPharma in Q1 2026 and has held it in 2 quarters since.
  • 144 funds tracked by Wall St. Rank held Zenas BioPharma as of Q2 2026.

Based on Capital International Investors's 13F filing for Q2 2026, filed 12 Aug 2026.